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STATE OF THE ART: CONCISE REVIEW
A Systematic Review of Restaging After Induction Therapy
for Stage IIIa Lung Cancer
Prediction of Pathologic Stage
Sara de Cabanyes Candela, MD,* and Frank C. Detterbeck, MD†‡
Background: Many clinicians use restaging after induction therapy
as a way to select patients for surgery.
Methods: A systematic review was conducted to define the reliability
of restaging tests after induction therapy for stage III(N2) lung cancer,
when compared with pathologic findings at surgery.
Results: A complete response at all sites carries a false-negative
(FN) rate of 50% for computed tomography and 30% for positron
emission tomography. Mediastinal node involvement has FN and
false-positive rates of 33% and 33% by computed tomography, and
25% and 33% by positron emission tomography. The FN rate of
invasive restaging is 22% by repeat mediastinoscopy, 14% by
esophageal ultrasound and needle aspiration in expert hands (reli-
able results are not yet available for endobronchial ultrasound), and
9% by primary mediastinoscopy done with optimal thoroughness.
These results are not significantly affected by the type of induction
therapy or the timing of restaging.
Conclusion: The ability to identify patients who have achieved
mediastinal downstaging other than by a careful primary mediasti-
noscopy is poor.
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Stage IIIa non-small cell lung cancer (NSCLC) accountsfor approximately one third of patients presenting with
this disease, and most of this stage group consists of patients
with malignant involvement of the mediastinal lymph nodes
(N2,3).1 Although the optimal management of these patients
is unclear, a common practice has become to consider pre-
operative (“induction”) therapy (chemotherapy  radiother-
apy [RT]) and possible surgery. Which patients are most
appropriate to select for this approach is also unclear,2 but it
is clear that a major prognostic factor is whether induction
therapy achieves clearance of N2,3 node involvement (down-
staging).3–5 This observation is based on the stage as deter-
mined after resection and raises the question of how well
preoperative restaging tests can predict the pathologic stage
and thus serve to select patients for resection.
Many physicians have, in fact, adopted the manage-
ment strategy for stage IIIa(N2) NSCLC of induction treat-
ment, followed by resection of patients believed to have been
downstaged. This approach is taken despite the fact that most
of the questions remain unanswered. Whether surgical resec-
tion adds further benefit over chemoradiotherapy is contro-
versial.2,3,6 Should patients with a good response to chemo-
radiotherapy undergo surgery because of a good response or
not undergo surgery because of a good response (or should
resection be avoided in those with a poor response or actually
be pursued provided there is no disease progression)2? Fi-
nally, whether restaging tests accurately predict the final
pathologic stage and which restaging test is best are unclear.
This article seeks to shed light on this last question.
We have conducted a systematic review of literature on
methods of restaging after induction therapy for patients with
stage IIIa(N2) NSCLC. The specific question addressed is
how reliably each method of restaging predicts the actual
pathologic stage. Methods of restaging include imaging (i.e.,
computed tomography [CT] or positron emission tomography
[PET]), needle-based biopsy techniques (e.g., esophageal
ultrasound or endobronchial ultrasound and needle aspiration
[EUS/EBUS-NA]), or surgical techniques (e.g.,1st time me-
diastinoscopy or repeat mediastinoscopy). The primary ques-
tion is how well restaging tests predict persistence or clear-
ance of tumor from mediastinal nodes, because this is often
cited as a criterion for selection of patients for resection. A
secondary question is how well restaging tests can predict
complete clearance of tumor from all sites (a pathologic com-
plete response [pCR]), potentially making surgery unnecessary.
The postinduction therapy pathologic stage is, in reality,
merely a surrogate end point for the real outcome measure of
interest: long-term survival without recurrence. One can also
pose the question of howwell restaging tests predict survival and
use the answers to select patients for a particular treatment
approach. These issues are not addressed in this article but are
the subject of another investigation. This review only addresses
the end point of the correlation between restaging tests and
actual pathologic stage, because many physicians already use
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restaging to select patients for surgery, without really knowing
how well the restaging techniques actually perform.
PATIENTS AND METHODS
A systematic review was conducted of data defining
parameters of reliability (sensitivity, specificity, false-nega-
tive [FN], and false-positive [FP] rates) of methods of restag-
ing of the mediastinum or the primary tumor after induction
therapy for NSCLC. The study question in this review was to
what extent the restaging test correlates with actual patho-
logic findings. Studies reporting on restaging with an end
point of survival rather than a microscopic assessment of
nodal involvement were excluded; such studies were saved
separately and comprise the subject of a separate review.
The point of the study question is to assess the ability
to select individual patients for a particular treatment ap-
proach. For example, if the absence of viable tumor at all sites
could be reliably predicted, such patients could avoid surgery.
On the other hand, if persistent N2 involvement is used to
preclude surgery (or clearance of the mediastinum is used to
select for surgery), then the FP rate (or the FN rate) in the
mediastinum is the key measure of a restaging test’s value.
These parameters allow assessment of a negative or positive
restaging test result in an individual patient. In contrast,
sensitivity and specificity are less clinically relevant because
they assess the test performance in a population of patients in
whom the true final result (presence or absence of cancer) is
already known. It must be emphasized that sensitivity and
specificity cannot be used to estimate the FN or FP rate
because they are calculated by entirely different formulas (the
only exception is perfect sensitivity or specificity [100%]
which does predict a FN or FP rate of 0, respectively, in most
cases). The parameter accuracy is avoided. Although this
term satisfies a desire for simplicity, condensing to a single
measure omits so much information that the number is not
useful to interpret test results either for an individual patient or
in comparison with other tests, and it varies with prevalence of
disease. Furthermore, it is misleading because it implies accu-
racy of a test result for a patient, which it does not.
Restaging tests that were considered are CT, PET, any
method of needle aspiration (i.e., EBUS, EUS, and transbron-
chial needle aspiration [TBNA]) or mediastinoscopy. The
gold standard against which a restaging test was compared
was microscopic assessment of mediastinal nodes or of the
primary tumor. A positive microscopic result was considered
acceptable, regardless of the technique used (e.g., mediasti-
noscopy, EUS/EBUS-NA, or thoracotomy), but a negative
result was not counted unless based on surgical exploration.
The thoroughness of intraoperative surgical evaluation may
vary,7 and unfortunately few studies defined this. The intent
appears to have been a lymphadenectomy in most studies, but
details of what was actually done were generally not provided.
A Medline search was conducted using the search terms:
lung cancer, non-small cell lung cancer, induction, neoadjuvant,
mediastinal staging, restaging, CT, computed tomography, PET,
PET-CT, positron emission tomography, endobronchial ultra-
sound, esophageal ultrasound, needle aspiration, mediastinos-
copy, and remediastinoscopy. The search was limited to English
language peer-reviewed articles published between 1980 and
2009. In addition, the reference lists of retrieved articles and
reviews and guidelines addressing induction therapy and restag-
ing were reviewed. The programs of major lung cancer meetings
from 2000 to 2009 were scanned, and authors of pertinent
unpublished studies were contacted. Articles were selected that
involved either prospective or retrospective clinical studies re-
porting on restaging (before resection) after induction treatment
(chemotherapy, RT, or a combination) if data on at least 20
patients was reported. Because of the paucity of articles on needle
aspiration methods of restaging, this was expanded to articles
reporting on these techniques in at least 10 patients. We intended
to limit the review to patients with biopsy-proven stage III
(N2,3) NSCLC, but many studies did not adhere to this strictly.
Therefore, we accepted all studies involving induction therapy
and restaging for NSCLC. However, we excluded articles that
focused primarily on Pancoast tumors. Furthermore, we ex-
cluded articles that did not allow calculation of test parameters.
The search strategy yielded a list of 170 articles. These
titles were scanned, and the abstracts of relevant article were
reviewed. Articles potentially meeting the inclusion criteria
were selected for full review. Together with the manual
search this produced a total of 129 articles that were reviewed
in full. In the case of duplicate articles, only one was chosen
that contained the most information. Articles were excluded
if a later, updated publication contained data on the same
patients. However, if overlapping series contained some
unique patients, both were included. This process resulted in
the selection of 32 articles, which met the study criteria, and
provided data addressing the study questions. Data extracted
included the number of patients, the method of restaging, type
of induction therapy, interval between completion of induc-
tion therapy and restaging, and the feasibility of performing
the restaging test (i.e., how often where adequate results
obtained when the technique was attempted).
Test parameters are defined in the usual manner: sen-
sitivity  true positive/(true positive  FN); specificity 
true negative/(true negative  FP); FN rate  FN/(true
negative  FN); FP rate  FP/(true positive  FP).8,9 We
prefer the more straightforward terms FN rate and FP rate
rather than negative predictive value ( 1  FN rate) or
positive predictive value ( 1  FP rate). Because the FN
and FP rates are markedly affected if the prevalence is very
low or very high,8,9 we excluded these values from calcula-
tion of averages if the prevalence was 10% or 90%.,
respectively. The specificity and FP rate of restaging was
often not evaluable because further confirmatory testing was
not generally done if microscopic evidence of N2,3 involve-
ment was found. In contrast, the requirement of confirmation
by thoracotomy of a negative restaging result allowed accu-
rate assessment of the FN rate and sensitivity. All results are
consistently reported relative to detecting the presence of
cancer; this involved recalculation of parameters from some
studies that reported results relative to the presence of a response
(i.e., the lack of cancer). Test parameters are calculated based
only on patients in whom the test was feasible, so that test results
can be interpreted. (However, in comparing sensitivity, the
reader must also take into account the feasibility.)
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Summary results involved simple averages without
weighting according to the study size. A formal meta-analysis
was not done because of the limited number of patients and
articles, the variety of induction treatments, and the variety of
subjective or objective criteria used to classify restaging test
results. Instead, details of these characteristics are included in
the tables and footnotes, so that the consistency and hetero-
geneity of the studies can be qualitatively assessed by the
reader. The quality of the articles was not rated, but use of an
appropriate confirmatory standard (as defined above) was
strictly required of included studies. However, the thoroughness
of the restaging procedures was rated according to a proposed
classification.7 An analysis of publication bias was not done. The
entire project including the search, data analysis, and writing
was conducted independently by the authors.
RESULTS
Prediction of pCR at All Sites
If complete clearance of tumor at all sites could be
reliably predicted, then these patients could be spared surgi-
cal resection. Studies of induction therapy have indeed shown
that a pCR is achieved in some patients, although the pro-
portion is low (20%).3,10–15 Studies that have evaluated
imaging tests for a pCR are summarized in Tables 1 and 2.
The prevalence of persistent disease is high in these studies,
consistent with the low pCR rates achieved after induction
therapy. Most importantly, though, the FN rate of a complete
response by imaging is high (approximately 50% by CT and
30% by PET).
The rate of pCR can also be related to the degree of
radiographic response. In studies of 20 patients who have
reported such data, a pCR was noted in approximately 57% of
patients (range, 0–100%) who had a radiographic CR,13,15–20
in 16% of patients (range, 0–35%) with a radiographic
PR,13,15–21 and in 0 to 10% of patients with radiographic
stable disease.13,15–18,20,21
The studies involving CT have shown a great deal
of variability (range of FN rate 0–100%). It is not clear
why this is the case; details of the CT imaging were
often not provided. Nevertheless, this variability does not
TABLE 1. CT for Pathologic Complete Response Assessment After Induction Therapy (pCR)
Study N
Sites
Assessed Technique
Level of
Thor
Crit for
Resid
Inductn
Ch/RT
%
Inductn
Ch %
Interval
(Wk)
Parameters for Detection of
Residual Cancer (%)
Prev Sens Spec FN FP
Margaritora et al.15 114 All CT — PR  SD 100 0 — 93 98 0 (100)a 7
Eberhardt et al.17 89 All CT — PR  SD 100 0 2–3 73 91 13 67 26
Faber et al.45 62 All CT — PR  SD 100 0 4–5 73 91 0 100b 29
Junker et al.46 40 All CT — PR  SD 100 0 7 83 88 0 100b 12
Strauss et al.21 31 All CT — PR  SD 100 0 — 77 100 0b — 23
Weitberg et al.19 27 All CT — PR  SD 100 0 4–6 55 100 33 0b 35
Cerfolio et al.22c 56 All CT B 90%2 41 59 6 66 68 42 60 31
Cerfolio et al.47c 34 All CT B PR  SD 21 79 2–104 84 94 0 100 9
Martini et al.13 125 All CT — PR  SD 0 100 4–6 85 94 26 55 12
Burkes et al.16 35 All CT — PR  SD 0 100 — 91 94 33 (67)a 6
Darwish et al.20 35 All CT — PR  SD 0 100 — 89 100 50b 0b 6
Rosell et al.48 28 All CT — PR  SD 0 100 — 96 100 100b (0)a,b 0
Pujol et al.18 25 All CT — PR  SD 0 100 — 84 100 100 0 0
Faber et al.45d 62 All CT — PR  SD 100 0 4–5 (52)d (97)d (10)d (75)b,d (43)d
Junker et al.46d 40 All CT — PR  SD 100 0 7 (33)d (92)d (13)d (25)b,d (88)d
Averagee All sites 94 31 54 15
Averagee forCh/RT15,17,19,21,45,46 72 95 8 67 22
Averagee for Ch13,16,18,20,48 89 98 62 18 5
Inclusion criteria: Studies of 20 patients reporting pathologic response assessment after induction therapy. Patients were proven to be N2,3 before induction therapy unless
otherwise noted.
a High prevalence (90%) makes FN rate unreliable.
b Calculation based on 5 patients in this category.
c Less than 50% had N2,3 node involvement.
d pCR or microscopic residual 10%.
e Excluding values in parentheses.
Ch, chemotherapy; Ch/RT, chemotherapy and radiotherapy; Crit for Resid, criteria for residual viable tumor (in some cases reported as the % decrease in size between a
preinduction and a postinduction CT); FN, false-negative rate (false negatives divided by all negative scans); FP, false-positive rate (false positives divided by all positive scans);
Inductn, induction therapy; Interval, Interval between last dose of chemotherapy (or RT) and the PET scan; Level of Thor, level of thoroughness of mediastinal staging;7 N, number
of evaluable patients; pCR, pathologic complete response (no viable tumor in resected tissue); PR, partial response; Wk, weeks; Prev, prevalence (of cancer at the site in question
at the time of restaging); SD, stable disease (50% decrease on CT); Sens, sensitivity; Spec, specificity.
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inspire confidence in the use of CT to predict a pCR.
The FN rate for CT appears particularly high after chemo-
radiotherapy, which is disappointing, because there is
little confidence that chemotherapy alone can cure
lung cancer.
The reliability of PET to detect residual tumor is more
consistent but still carries an unacceptably high FN rate
(30%). Most of the PET studies addressed only detection of
residual cancer at the primary site. Subgroup analysis does
not identify a group in which a negative PET is reliable
(Table 2). The FP rate appears to be quite low in studies
involving induction chemotherapy without radiation and in
studies involving quantitative PET assessment (by the stan-
dardized uptake value or SUV). Cerfolio et al.,22 using a
quantitative change from pre to postinduction PET, found
better prediction of pCR after chemotherapy than chemora-
diotherapy and after lower than higher doses of RT. Review
of the results in Table 2 suggests this may be driven by
differences in the FP rather than the FN rate. It should be
noted that despite its name, SUV is not standardized, and
there is significant variation between scanners and scans due
to multiple factors.23,24
One study has analyzed in detail both CT and PET to
define quantitatively what degree of change after induction
TABLE 2. PET for Pathologic Response Assessment After Induction Therapy (pCR at Primary or All Sites)
Study
Eval
Pts
Sites
Assessed Technique
Level
of
Thor
Crit for
Resid
Inductn
Ch/RT
%
Inductn
Ch
Interval
(Wk)
Parameters for Detection of
Residual Cancer (%)
Prev Sens Spec FN FP
Ryu et al.49 26 All PET B Visual 100 0 2 69 67 63 45 20
Ryu et al.49 26 All PET B SUV 3 100 o 2 74 88 67 33 12
Cerfolio et al.22a 56 All PET B 80%2 41 59 6 66 100 90 0 5
Cerfolio 03a 34 All PET B SUV 3 21 79 2–104 84 97 67b 33b 3
Average All sites 88 72 28 10
Eschmann et al.50 47 Prim PET B SUV 2.5 100 0 2 71 95 80 20 5
Hellwig et al.51a 37 Prim PET B Visual 100 0 4 70 81 64 42b 26
Choi et al.52 30 Prim PET B Kineticc 100 0 2 53 86 81 13 20
Ryu et al.49 26 Prim PET B Visual 100 0 2 69 67 63 45 20
Ryu et al.49 23 Prim PET B SUV 3 100 0 2 74 88 67 33 12
Pöttgen et al.53 20 Prim PET/CT A 50%2 100 0 1 65 31 86 60 20
Ohtsuka et al.54 22 Prim PET B visual 82 18 4–48 91 80 0b (100)b,d 11
Akhurst et al.55e 52 Prim PET B Visual 20 71 — 98 90 67 (71)d 2
Cerfolio et al.47a 34 Prim PET B SUV 3 21 79 2–104 94 97 100b (33)b,d 0
Port et al.56a 23 Prim PET B 50%2 0 100 2 96 41 100 (93)d 0
Pöttgen et al.53f 20 Prim PET/CT A 50%2 100 0 1 (30)f (67)f (93)f (13)f (20)f
Port et al.56a,f 23 Prim PET B 50%2 0 100 2 (74)f (58)f (100)f (57)f (0)f
Averageg Primary site 76 71 36 12
Averageg at primary site, Ch/RT49–54 76 59 36 16
Averageg at primary site, Ch47,55,56 76 89 — 1
Averageg at primary site, Visual PET49,51,54,55 79 49 44 15
Averageg at primary site, quantitative PET after Induction therapy47,49,50 93 82 27 6
Averageg at primary site,pre- vs. postinduction therapy PET (50% 2)53,56 36 93 60 10
Inclusion criteria: Studies of 20 patients reporting pathologic response assessment after induction therapy. Patients were proven to be N2,3 before induction therapy unless
otherwise noted.
a Less than 50% had N2,3 node involvement.
b Calculation based on 5 patients in this category.
c Quantitative kinetic PET imaging, with a glucose metabolic rate of 0.076 mol/min/g considered positive.
d High prevalence (90%) makes FP rate unreliable.
e Data on preinduction stage not reported.
f pCR or microscopic residual.
g Excluding values in parentheses.
Ch, chemotherapy; Ch/RT, chemotherapy and radiotherapy; Crit for Resid, criteria for residual viable tumor (in some cases reported as the % decrease in quantitative uptake
between a preinduction and a postinduction PET); FN, false-negative rate (false negatives divided by all negative scans); FP, false-positive rate (false positives divided by all positive
scans); Inductn, induction therapy; Interval, interval between last dose of chemotherapy (or RT) and the PET scan; Level of Thor, level of thoroughness of mediastinal staging;7 N,
number of evaluable patients; pCR, pathologic complete response (no viable tumor in resected tissue); Prev, prevalence (of cancer at the site in question at the time of restaging);
Prim, primary tumor site; Sens, sensitivity; Spec, specificity; SUV, standard uptake value.
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treatment best predicts a pCR.22 CT did not perform well,
even with a 90% decrease in the size of the primary cancer
(FN rate 60%, FP rate 31%).22 The optimal change in SUV in
the primary lesion by PET was found to be a80% reduction
(FN rate 0%, FP rate 5%). Whether this can be duplicated in
a validation dataset from another institution remains to be
seen. In summary, CT imaging is unable to reliably predict
complete eradication of all viable tumor, and PET is gener-
ally also not sufficiently reliable, although a quantitative
change of 80% holds promise.
TABLE 3. Mediastinal Restaging by Imaging After Induction Therapy (N0,1 vs. N2,3)
Study N Technique
Level
of
Thor
Crit for
Resid
Inductn
Ch/RT
%
Inductn
Ch %
Interval
(Wk)
Percentage
Prev Sens Spec FN FP
Trodella et al.4 56 CT — — 100 0 3–4 23 92 77 9 8
De Leyn et al.28 30 CT B 1 cm 0 100 3–4 57 59 62 47 34
Mateu-Navarro et al.57 24 CT — — 0 100 4 50 42 75 44 38
Lardionois et al.43 24 CT B 1 cm 0 100 — 38 56 73 27 44
Ohtsuka et al.54 22 CT B 1 cm 82 18 4–48 41 67 62a 27a 45
Cerfolio et al.47b,c 34 CT B 1 cm 21 70 2–104 (9)c (40)c (99)c (6)c,d (25)c
Averaged 190 CT 63 70 31 34
Cerfolio et al.58 93 PET/CT A SUV 3 100 0 4–10 37 62 88 20 25
Eschmann et al.50 56 PET B SUV 2.5 100 0 2 55 77 68 29 25
Ryu et al.49c,e 26 PET B Visual 100 0 2 (26)c (58)c (93)c (12)c (30)c
Ohtsuka et al.54 22 PET B Visual 82 18 4–48 41 67 62a 27a 45
Stigt et al.29 25 PET C SUV  79 21 2 52 85 33 33 42
Hellwig et al.51b 33 PET B Visual 70 28 5 24 50 88 15 43
Akhurst et al.55f 54 PET B Visual 20 71 — 33 67 61 21 54
Cerfolio et al.47b,c 34 PET B SUV 3 21 79 2–104 (9)c (74)c (100) c (3)c,d (0)c
De Leyn et al.28 30 PET/CT A Visual 0 100 3–4 57 77 92 25 7
De Leyn et al.28 30 PET B Visual 0 100 3–4 57 71 69 36 25
Hoeckstra et al.30 25 PET B Visual 0 100 3–4 50 50 71 33 34
Port et al.56b 25 PET B SUV 2.5 0 100 2 20 20 71 23 40
Averageg 453 PET 63 70 26 34
Average for PET/CT28,58 70 90 23 16
Average for PET28–30,49–51,54–56 60 66 27 38
Average for Ch/RT49,50,55,58 66 72 23 49
Average for Ch28,30,55,56 57 74 30 29
Average for interval 4 wk28–30,49,50,56 63 68 30 30
Average for interval 4 wk51,54,58 60 79 21 38
Average for quantitative assessment29,50,56,58 61 65 26 33
Average for visual assessment28,30,49,51,54,55 64 75 26 35
Average for N0 vs. N1–354–56 74 68 36 26
Inclusion criteria: Studies of20 patients reporting results of mediastinal node restaging (N2,3) after induction therapy. Patients were proven to be N2,3 before induction therapy
unless otherwise noted.
a Calculation based on 5 patients in this category.
b Less than 50% had N2,3 node involvement.
c Analysis done per node; not comparable with per patient analysis.
d Unreliable because prevalence 10%.
e Station 10 nodes included in calculation of N2,3 involvement.
f Data on preinduction stage not reported.
g Excluding values in parentheses.
Ch, chemotherapy; Ch/RT, chemotherapy and radiotherapy; FN, false-negative rate (false negatives divided by all negative scans); FP, false-positive rate (false positives divided by all
positive scans); Interval, interval between last dose of chemotherapy (or RT) and the PET scan; Level of Thor, level of thoroughness of mediastinal staging;7 N, number of evaluable patients;
Inductn, induction therapy; Prev, prevalence (of cancer at the site in question at the time of restaging); Sens, sensitivity; Spec, specificity; SUV, standard uptake value.
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Mediastinal Restaging by Imaging (CT and PET)
The major focus of reassessment after induction ther-
apy is whether there is malignant involvement of the medi-
astinal lymph nodes. Studies addressing this issue using
imaging techniques are summarized in Table 3. Surprisingly,
few studies have formally evaluated the reliability of restag-
ing by CT (six studies involving 190 patients). The results
support the general belief that CT is a poor restaging test (FN
and FP rates of approximately 40%). Even if one focuses only
on the patients without a radiographic response to induction
therapy (stable disease), a substantial portion (9–36%) have,
in fact, been downstaged to ypN0,1.16,25–27 Therefore, neither
a complete response nor a complete lack of response in the
mediastinum by CT is reliable in identifying those who have
or have not been downstaged.
Ten studies involving 398 patients have evaluated the
ability of PET to determine downstaging from N2,3 to
ypN0,1 (Table 3). PET restaging is associated with a high FN
(25%) and FP rate (33%). Subset analyses do not reveal a
group in which PET performed sufficiently well to serve as a
restaging test (Figure 1). The results for PET imaging are
quite consistent among studies, with the exception of a low
FP rate in one study28 and a low specificity in another.29 An
explanation for these outliers is not readily apparent.
In a retrospective analysis, Cerfolio et al. found that
approximately 1 month was the optimal timing of a restaging
PET/CT after chemoradiotherapy. The end point in the analysis
was both the overall stage and the mediastinal node status as
suggested by restaging PET/CT versus the result of biopsy or
resection. Subset analysis of all studies did not show a difference
between PET restaging in less than or greater than 4 weeks.
However, this included both studies involving chemoradiother-
apy and chemotherapy alone. It is possible that this may make a
difference in the optimal timing of PET. Others have suggested
that an early PET response (after one dose of chemotherapy) is
highly predictive of outcomes (but have not reported results of
early PET with respect to mediastinal downstaging).30 We were
not able to analyze an interaction between early versus late PET
imaging and induction chemotherapy versus chemoradiotherapy
further from the data reported.
Mediastinal Restaging by Invasive Procedures
Five studies involving 515 patients (Table 4) report
results of repeat mediastinoscopy for restaging of stage III
NSCLC (as well as other studies involving smaller overlap-
ping cohorts of patients). All patients had undergone previous
mediastinoscopy (not EBUS), which involved biopsy of stations
2R, 2L, 4R, 4L, and 7. All groups used a similar technique
consisting of opening the previous scar and entering the medi-
astinum through the left paratracheal space, followed by exten-
sion of the dissection to the right paratracheal space. All authors
used a traditional mediastinoscope except De Leyn et al., who
used a videomediastinoscope. The thoroughness of the medias-
tinal evaluation in these studies is high.
Remediastinoscopy has been found to be safe, although
one death has been reported.31 The feasibility of remediasti-
noscopy was 87%. Remediastinoscopy was considered valid
when all previously positive stations were biopsied, but two
studies defined biopsy of any tissue as sufficient.32,33 There is
no apparent difference in the feasibility whether RT was
given or whether the procedure was performed earlier or
later. It has been suggested that the low feasibility reported by
De Leyn et al.28 was due to the use of the larger videomedi-
astinoscope, although in general videomediastinoscopy per-
forms better than traditional mediastinoscopy.34
Remediastinoscopy quite consistently carries a high FN
rate (22%). This is not worse if induction therapy included
RT; in fact, the FN rate is lower after induction chemoradio-
therapy versus chemotherapy alone (15% versus 33%). Fur-
ther subgroup analyses were not able to be performed from the
data reported.
A prospective multicenter study has evaluated thoraco-
scopic restaging after previous mediastinoscopy and induc-
tion therapy in 70 patients,35 but only preliminary data are
available. The feasibility of thoracoscopic restaging was
74%, although complete ipsilateral restaging was possible in
only 57%. The reported test parameters are sensitivity 75%,
specificity 100%, FN rate 24%, and FP rate 0%. However, it
is not clear whether these values included all patients, all
feasible procedures, or only procedures involving complete
restaging.
Several authors have reported results of mediastinal
restaging techniques that are based on needle aspiration,
involving 191 patients (Table 4). This involves several
smaller studies of EUS, a larger multiinstitutional study of
EBUS and one study of TBNA without node visualization. The
level of thoroughness of mediastinal staging in these studies is
much more limited than for remediastinoscopy (average number
of node stations sampled per patient of 1.2,36 1.4,37 and 1.638).
The feasibility of performing an “adequate” EBUS/EUS evalu-
ation of the mediastinum is high (97%).
The average FN rate of needle-based techniques of
mediastinal restaging is surprisingly good (14%). This is
surprising, because in general, needle-based mediastinal stag-
ing has been associated with a FN rate of approximately 20 to
Assessment of Subgroups by PET
er
ce
nt
P
False Neg False Pos Sensitivity Specificity
FIGURE 1. Subgroup analysis of positron emission tomog-
raphy (PET) for mediastinal node restaging.
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25%,34,39 making it hard to believe it is better in the setting of
restaging. The FN rate of 0 in the study of TBNA (without
visualization) is particularly surprising and can perhaps be
explained by the small study size and patient selection.
Exclusion of this study results in a FN rate of 18%. Similarly,
the study by Annema et al37 included selected patients with
nodes in stations 7 or 4L that were easily accessible by
EUS-NA. The study by Herth et al38 was prospective and
very carefully done, but the unusually high prevalence of
persistent mediastinal disease renders the FN rate unstable.
However, this is the only study that allows assessment of the
FP rate, because resection was carried out in all patients,
regardless of the EBUS results. Although needle-based tech-
niques have occasionally produced FP results,40–42 none were
found.38 The limited number of studies did not allow subset
analyses to be performed.
Two studies addressed the performance of first-time
mediastinoscopy for restaging in a total of 85 patients.43,44 All
these patients originally had mediastinal node involvement
documented by a needle technique. These studies used either
video-assisted mediastinoscopy or transcervical extended me-
diastinal lymphadenectomy and a very thorough mediastinal
evaluation. Neither of the studies reported the interval be-
tween the conclusion of induction treatment and restaging,
and most of patients underwent induction chemotherapy
alone. Results of these studies are shown in Table 4.
DISCUSSION
Many physicians have adopted the treatment strategy of
induction therapy followed by resection of those patients
thought to be downstaged. However, many aspects of this are
TABLE 4. Mediastinal Restaging by Invasive Biopsy After Induction Therapy (N0,1 vs. N2,3)
Study N Technique
Level
of Thor Feasb
Inductn
Ch/RT
%
Inductn
Ch %
Interval
(Wk)
Percentagea
Prev Sens Specc FN FPc
Stamatis et al.32 165 reMed B 97d 100 0 4 29 74 (100) 14 (0)
Meerschaut et al.59e 112 reMed B 82f — — — 27 71 (100) 9 (0)
Marra et al.33 104 reMed B 98d 100 0 3 38 51 (100) 21 (0)
De Waele et al.31 104 reMed C 100 24 76 4–6 55 70 (100) 27 (0)
De Leyn et al.28 30 reMed B 60 0 100 3–4 56 50 (100) 38 (0)
Averageg 515 reMed 87 63 — 22 —
Average: Ch/RT31–33 reMed 63 — 15 —
Average: Ch28,31 reMed 60 — 33 —
Herth et al.38 124 EBUS-NA C 100 0 100 4 94 76 100 (80)h 0
Annema et al.37 17 EUS-NA C 89 0 100 3 65 67 (100) 33 (0)
Varadarajulu et al.60 14 EUS-NA C 93 100 0 3 54 86 (100) 14 (0)
Stigt et al.29 25 EUS-NA C — 79 21 2 52 92 (100) 8 (0)
Kunst et al.36 11 TBNA C 93 86 14 2 60 100 (100) 0 (0)
Averageg Needle techniques 94 84 — 14 —
Zielinski et al.44 63 1° Med A 100 14 86 — 37 96 (100) 3 (0)
Lardinois et al.43 22 1° Med A 100 0 100 — 41 82 (100) 15 (0)
Average 85 1° Med 89 — 9 —
Jaklitsch et al.35 53 VATS B 69 68 97 — 54 62 (100) 24 (0)
Inclusion criteria: Studies reporting results after induction therapy of repeat mediastinoscopy in 20 patients, or EBUS, EUS, or TBNA for mediastinal node restaging (N0,1
vs., N2,3) in 10 patients. In all studies, the vast majority of patients had N2,3 involvement before induction therapy.
a Of patients in whom the procedure was considered feasible.
b Defined as successful biopsy of previously involved node stations unless otherwise noted.
c Technically not assessable because no further biopsies done.
d Defined as biopsy of any tissue.
e Data on preinduction stage not reported.
f No definition provided.
g Excluding values in parentheses.
h Unreliable because prevalence 90%.
1° Med, primary (1st time) mediastinoscopy; Ch, chemotherapy; Ch/RT, chemotherapy and radiotherapy; EBUS-NA, endobronchial ultrasound guided needle aspiration;
EUS-NA, esophageal ultrasound guided needle aspiration; FN, false-negative rate (false negatives divided by all negative scans); FP, false-positive rate (false positives divided by
all positive scans); Feas, feasibility of adequately performing the procedure; Inductn, induction therapy; Interval, interval between last dose of chemotherapy (or RT) and the
remediastinoscopy; Level of Thor, level of thoroughness of mediastinal staging;7 N, number of evaluable patients; Prev, prevalence (of cancer at the site in question at the time of
restaging); reMed, remediastinoscopy; Sens, sensitivity; Spec, specificity; TBNA, transbronchial needle aspiration; VATS, video-assisted thoracic surgery (thoracoscopy).
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unclear, including whether the strategy itself is beneficial,
what induction treatment should be given, or how patients
should be selected for this approach. Perhaps most surprising
is how convinced many are that the criteria for selection of
patients for subsequent resection are well established. It is
often forgotten that downstaged patients have been identified
after resection. Use of downstaging to select patients for
surgery requires a reliable method of identifying them before
resection.
The most widely used method of selecting patients for
surgery is the radiographic response by CT to induction
therapy. This occurs despite the fact that virtually every study
that has analyzed this has found little, if any, correlation
between the response by CT and pathologic findings after
resection. This review also confirms that a normal-appearing
mediastinum after induction therapy carries a 30% FN rate
and an abnormal mediastinum a 30% FP rate. Therefore, use
of CT alone to either select patients for or exclude them from
surgery is not justified, at least not if the goal is to only resect
those patients who are downstaged. Furthermore, a complete
response by CT cannot be used to justify avoidance of
resection because of a 50% FN rate. Although a radiographic
response makes the patient and the physician feel good, it
provides little information about the presence of absence of
viable tumor.
PET imaging is also commonly used to predict down-
staging, although it is well recognized that RT can cause
fluorodeoxyglucose uptake due to inflammation. Although
PET performs somewhat better than CT, approximately one
fourth of patients with a negative (“cleared”) mediastinum by
PET still have pN2 involvement and approximately one third
of those with persistent PET uptake in the mediastinum do
not. Surprisingly, whether RT was given has no impact on
these results. Indeed, no patient subsets could be identified in
whom restaging PET is reliable. Finally, a complete response
by PET in all sites cannot justify omitting resection: one third
of such patients still have viable tumor. Perhaps more sophis-
ticated assessments such as the percent change in PET activ-
ity can be used. However, it must be emphasized that such
assessments require great attention to detail to ensure consis-
tency in the measurements (i.e., the scanner, the region of
interest, and the amount and timing of fluorodeoxyglucose).
Remediastinoscopy has been shown to be feasible and
safe in experienced hands, but few institutions are comfort-
able with this technique. Because the results are disappoint-
ing (FN rate 25%), it is unlikely this will change. EBUS or
EUS and needle aspiration are gradually becoming more
widely available. The results seem to be slightly better than
for remediastinoscopy (FN rate 15%), but the number of
studies is limited, and it remains to be seen whether these will
hold up as the procedure is practiced more widely (outside of
the pioneering centers and in less well-selected patients).
Primary mediastinoscopy performs fairly well, consistent
with the performance of primary mediastinoscopy in general
(especially the more thorough variations such as video-
assisted mediastinal lymphadenectomy and transcervical ex-
tended mediastinal lymphadenectomy).39 However, this re-
quires avoidance of mediastinoscopy in the initial staging.
Often little thought is given to the eventual treatment strategy
at the time that patients are first evaluated and staged.
A summary of the sensitivity and FN rates of various
methods of restaging of the mediastinum is shown in Figures
2A, B. These results suggest that restaging to select only the
patients who have been downstaged in the mediastinum for
resection leaves much to be desired. Certainly, restaging by
imaging alone is highly unreliable (both FN and FP rates are
high). Furthermore, for those patients who have not been
downstaged (by invasive restaging), it is unclear whether
their survival is better with surgical resection or an alternative
therapy (provided no distant metastases have appeared).2 It
should be remembered that the majority of studies of induc-
tion therapy and resection took the approach of resection of
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FIGURE 2. Summary of performance of mediastinal restaging tests. A, Average false-negative rates; B, average sensitivity.
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all patients regardless of restaging (unless distant metastases
had appeared). Restaging by EBUS/EUS is possibly accept-
able if expertise is available or 1st time mediastinoscopy if
thoughtful planning at presentation provided microscopic
confirmation of N2,3 involvement without mediastinoscopy.
This review has only addressed the ability of restaging
tests to reliably predict mediastinal downstaging (ypN0,1)
and complete eradication of all tumor (pCR). This represents
a surrogate end point that has been correlated with the
ultimate goal of long-term cure. Studies linking characteris-
tics of patients after induction therapy directly to long-term
survival are beyond the scope of this review.
In summary, we have carried out a systematic review of
studies addressing methods of restaging after induction ther-
apy for stage III NSCLC, when compared with actual patho-
logic findings in the mediastinal nodes or primary site. Al-
though these methods of restaging are commonly used to
select or exclude patients from surgery, the data show them to
be quite unreliable. In particular, mediastinal downstaging by
CT, PET, or remediastinoscopy carry a FN rate of 20 to 30%.
EUS and EBUS may perform slightly better, but data are
limited. Primary mediastinoscopy seems to be the most reli-
able method of assessment. Ideally, initial invasive staging of
the mediastinum should be done by a needle-based technique,
so that primary mediastinoscopy can be used for restaging.
Treatment approaches involving induction therapy and resec-
tion of downstaged patients should not be based on the
assumption that imaging tests can predict the status of the
mediastinal nodes.
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